antinevralgic sinus
zentiva k.s. - combinatii - compr. film. - alte analgezice si antipiretice anilide (inclusiv combinatii)
antinevralgic sinus
zentiva k.s. - republica ceha - combinatii - compr. film. - alte analgezice si antipiretice anilide (inclusiv combinatii)
antinevralgic sinus
zentiva k.s. - republica ceha - combinatii (paracetamolum+cafeinum+phenylephrinum) - compr. film. - alte analgezice si antipiretice anilide (inclusiv combinatii)
antinevralgic forte 250 mg + 250 mg + 50 mg comprimate
sanofi romania srl - acid acetylsalicylicum + paracetamolum + cofeina - comprimate - 250 mg + 250 mg + 50 mg
antinevralgic forte
zentiva, k.s. - combinatii - compr. - alte analgezice si antipiretice acid salicilic si derivati
antinevralgic forte
zentiva s.a. - romania - combinatii - compr. - alte analgezice si antipiretice acid salicilic si derivati
antinevralgic forte
zentiva s.a. - romania - combinatii (acid acetylsalicylicum+paracetamolum+cafeinum) - compr. - 250mg/250mg/50mg - alte analgezice si antipiretice acid salicilic si derivati
firmagon
ferring pharmaceuticals a/s - degarelix - prostate neoplasme - terapia endocrină - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostate neoplasme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
zometa solutie perfuzabila 4 mg/100 ml
novartis pharma ag - acid zoledronicum - solutie perfuzabila - 4 mg/100 ml